Agenus (AGEN) Competitors

Agenus (NASDAQ:AGEN) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Do analysts prefer AGEN or EBS?

Agenus presently has a consensus target price of $15.50, indicating a potential upside of 234.77%. Emergent Biosolutions has a consensus target price of $14.33, indicating a potential upside of 61.96%. Given Agenus' higher probable upside, equities research analysts plainly believe Agenus is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Emergent Biosolutions	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, AGEN or EBS?

Agenus has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Which has better valuation and earnings, AGEN or EBS?

Emergent Biosolutions has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$103.46M	1.43	-$227.21M	-$7.15	-0.65
Emergent Biosolutions	$1.04B	0.45	-$190.60M	$2.45	3.61

Do insiders and institutionals believe in AGEN or EBS?

61.5% of Agenus shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 5.5% of Agenus shares are held by company insiders. Comparatively, 1.2% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media prefer AGEN or EBS?

In the previous week, Agenus had 6 more articles in the media than Emergent Biosolutions. MarketBeat recorded 18 mentions for Agenus and 12 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.86 beat Agenus' score of 0.31 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Emergent Biosolutions	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AGEN or EBS more profitable?

Emergent Biosolutions has a net margin of 16.38% compared to Agenus' net margin of -167.52%. Emergent Biosolutions' return on equity of 24.63% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	-167.52%	N/A	-81.04%
Emergent Biosolutions	16.38%	24.63%	8.97%

Summary

Emergent Biosolutions beats Agenus on 12 of the 16 factors compared between the two stocks.